The presence and distribution of angiotensinogen and angiotensin II (All) were demonstrated in rat pituitary by immunocytochemical staining with the avidin-biotin-peroxidase method, using primary polyclonal antibodies specific for angiotensinogen and All. Silver enhancement of the reaction product was used to intensify lightly stained areas. Attempts were made to identify immunopositive cells by colocalization studies with antisera against luteinizing hormone, prolactin and S-100, a glial cell protein. In the anterior pituitary, angiotensinogen-immunoreactivity was observed in cells lining follicle-like structures. These cells, which were irregularly shaped and had processes extending between the glandular cells, did not colocalize with any of the reference antisera and are therefore of unknown cell type. The follicular endothelium was also immunopositive for angiotensinogen. After silver intensification, dispersed immunoreactive glandular cells were consistently observed in the anterior lobe. A proportion of these costained for luteinizing hormone, but not prolactin or S-100, indicating their identity as gonadotrophs. In the posterior pituitary, angiotensinogen immunostaining was associated only with the vasculature, while groups of immunopositive cells were observed in the medial region of the intermediate lobe after silver enhancement. All-immunoreactivity was observed in large cells preferentially located a t the poles of the anterior pituitary which also costained for luteinizing hormone. No staining was observed in either the posterior or intermediate lobes. The presence of immunoreactive angiotensinogen in all three lobes of the pituitary suggests that there a r e sites, in addition to gonadotrophs, at which the intracellular production of All could occur.The octapeptide angiotensin IT (AII) regulates the release of several hormones from the anterior pituitary. In both in vivo and in vifro, A11 is a stimulus for the secretion of prolactin (PRL) (1-4), adrenocorticotrophin (ACTH) ( 5 , 6), luteinizing hormone (LH) (7) and P-endorphin (8). These effects may be mediated by specific A11 receptors located on pituitary cells (9-11) or A11 may function through intermediate releasing factors, such as corticotrophin-releasing factor, as is the case for AH-stimulated release of ACTH (1 2-1 5). Of interest is the possibility that the pituitary is synthesizing and secreting AII, as part of an endogenous reninangiotensin system (RAS), to directly alter pituitary function.Several observations support the idea of a functioning RAS in the pituitary: 1) the demonstration of renin (16-19) and converting enzyme in the pituitary (20-23); 2) the detection of renin mRNA in pituitary extracts (24); 3) the identification and HPLC characterization of A11 from the hypophysis (25, 26); 4) the colocalization, by immunocytochemistry, of both renin and A11 in the rat gonadotroph (19,27) or human lactotroph (28); and 5) the demonstration of specific A11 receptors in the pituitary (9-1 1). However, the existence of angiotensino...